Shattuck Labs (STTK) to Release Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is expected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Stock Down 7.6 %

Shares of NASDAQ STTK opened at $1.22 on Tuesday. The company’s 50-day simple moving average is $1.24 and its 200-day simple moving average is $1.77. Shattuck Labs has a 52-week low of $0.94 and a 52-week high of $11.76. The firm has a market cap of $58.24 million, a price-to-earnings ratio of -0.80 and a beta of 1.70.

Insider Transactions at Shattuck Labs

In other Shattuck Labs news, Director Redmile Group, Llc purchased 133,371 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average cost of $1.25 per share, with a total value of $166,713.75. Following the completion of the purchase, the director now owns 5,539,724 shares in the company, valued at approximately $6,924,655. This represents a 2.47 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

STTK has been the topic of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research note on Friday, November 15th. Four analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.67.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.